Buscar
Mostrando ítems 1-6 de 6
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
(MDPI, 2021)
A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ...
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
(MDPI, 2020)
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is ...
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
(MDPI, 2020)
Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in ...
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
(MDPI, 2020)
Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year ...
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
(MDPI, 2020)
Current developments in the treatment of genitourinary tumors underline the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting. The detection of circulating tumor cells (CTCs) ...
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
(MDPI, 2021)
Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for metastatic UC. PD-L1 expression levels in UC tumors ...